About CAAX prenyl protease 1 homolog
CAAX prenyl protease 1 homolog (ZMPSTE24) is a protein
from Homo sapiens identified by UniProt accession
O75844, 475 residues long.
MolForge cross-references it against 0 known binders and
298 disease associations.
Target properties
| Protein name | CAAX prenyl protease 1 homolog |
| UniProt accession | O75844 |
| Gene | ZMPSTE24 |
| Organism | Homo sapiens |
| Length | 475 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (298)
Diseases linked to this target (Open Targets).
- mandibuloacral dysplasia with type B lipodystrophy · score 0.80
- Lethal restrictive dermopathy · score 0.74
- restrictive dermopathy 1 · score 0.60
- Hutchinson-Gilford progeria syndrome · score 0.38
- restrictive dermopathy · score 0.37
- mandibuloacral dysplasia · score 0.19
- genetic disorder · score 0.19
- infect · score 0.08
- infection · score 0.08
- Alopecia universalis · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75844-F1 | alphafold | PREDICTED | 89.46 | — |
Amino-acid sequence (475 residues)
MGMWASLDAL WEMPAEKRIF GAVLLFSWTV YLWETFLAQR QRRIYKTTTH VPPELGQIMD SETFEKSRLY QLDKSTFSFW SGLYSETEGT LILLFGGIPY LWRLSGRFCG YAGFGPEYEI TQSLVFLLLA TLFSALTGLP WSLYNTFVIE EKHGFNQQTL GFFMKDAIKK FVVTQCILLP VSSLLLYIIK IGGDYFFIYA WLFTLVVSLV LVTIYADYIA PLFDKFTPLP EGKLKEEIEV MAKSIDFPLT KVYVVEGSKR SSHSNAYFYG FFKNKRIVLF DTLLEEYSVL NKDIQEDSGM EPRNEEEGNS EEIKAKVKNK KQGCKNEEVL AVLGHELGHW KLGHTVKNII ISQMNSFLCF FLFAVLIGRK ELFAAFGFYD SQPTLIGLLI IFQFIFSPYN EVLSFCLTVL SRRFEFQADA FAKKLGKAKD LYSALIKLNK DNLGFPVSDW LFSMWHYSHP PLLERLQALK TMKQH
Explore CAAX prenyl protease 1 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets